Completion of vaccination and enrollment in Sci-B-Vac® PROTECT and CONSTANT Phase 3 studies, respectively Encouraging early immunologic data observed in Phase 1/2a study of VBI-1901 for the treatment of recurrent glioblastoma VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical...
Read More
Categories
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that initial clinical data from the Phase 1/2a study of VBI-1901 in recurrent Glioblastoma (GBM) patients will be presented in a...
Read More
Vaccination complete in 1,537 subjects in PROTECT Phase 3 study No vaccine-related adverse events have been observed to-date Top-line data expected mid-2019 VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced...
Read More
Presentation to feature complete safety and immunogenicity dataset from the Phase 1 clinical study of VBI-1501 Oral presentation at IDWeek 2018 on Saturday, October 6th, 2018, at 11:10 AM PT VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company,...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of three Scientific and Clinical Advisory Boards (SABs) consisting of leading experts in infectious disease and immuno-oncology research and vaccine...
Read More
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modification Intermediate-dose study arm: enrollment complete Initial immunologic data from low and intermediate-dose cohorts expected in the fourth quarter 2018 VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”, the “Company”) is the subject of an article published in Globes, Israel business news, on September 12, 2018, written by Gali Weinreb (the “Article”) alleging that VBI failed to meet its responsibilities of disclosure regarding...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company, today announced the appointment of Christopher McNulty as Chief Financial Officer and Head of Business Development, effective immediately. Mr. McNulty is an accomplished financial executive in the biopharmaceutical and medical device...
Read More
Media Contact
Nicole Anderson, Communications Executive
Telephone: (617) 830-3031 x124
Email: ir@vbivaccines.com